Cobimetinib | Radio Compass News

FDA Approves Oral MEK Inhibitor Cobimetinib Histiocytic Neoplasms Led by MSKCC

01 Nov 2022 //

MSKCC

Revolution Medicines to Present Interim Data at ENA 2020 Ph 1b/2 Trial RMC-4630

12 Oct 2020 //

GLOBENEWSWIRE

Roche`s phase III IMspire150 study of Tecentriq plus Cotellic & Zelboraf

13 Dec 2019 //

PHARMABIZ

REVOLUTION Medicines Announces Dosing Patient in RMC-4630-02 with RMC-4630

18 Sep 2019 //

PR NEWSWIRE

Roche/Exelixis` Cotellic fizzles in pivotal melanoma study

21 Jun 2019 //

ENDPTS

Novartis wins key adjuvant Taf/Mek approval in Europe

29 Aug 2018 //

PM LIVE

TESARO Collaborates to Evaluate ZEJULA® With Anti-PD-L1 therapy & MEK Inhibitor

05 Jun 2018 //

GLOBENEWSWIRE

Greek Health Minister Takes Issue With Roche`s Withdrawal of Cancer Medicine

01 Nov 2017 //

RAPS

Anvisa Suspends Roche`s Trade in lot B1009M8 of The Medicinal Product Cotellic (hemifumarate of cobimetinib)

11 May 2017 //

ANVISA

Enforcement Report - Week of April 12, 2017

12 Apr 2017 //

FDA

Hoffmann-La Roche Ltd. Recalls Cobimetinib Fumarate

21 Mar 2017 //

HEALTH CANADA

Novartis wins CHMP nod for drug combo against some lung cancers

25 Feb 2017 //

REUTERS

Competition Stalls Roche Margin Growth; Drugmaker Commits to Diabetes Unit

02 Feb 2017 //

REUTER

Roche pushes Tecentriq combos into PhIII melanoma trials

07 Nov 2016 //

PHARMATIMES

NICE nods for Tagrisso, Cimzia and Zepatier

27 Oct 2016 //